{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:30:58Z","timestamp":1648989058673},"reference-count":39,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2007]]},"DOI":"10.2169\/naika.96.787","type":"journal-article","created":{"date-parts":[[2012,7,31]],"date-time":"2012-07-31T22:31:47Z","timestamp":1343773907000},"page":"787-804","source":"Crossref","is-referenced-by-count":0,"title":["Recent Therapeutic Strategy for Follicular Lymphoma"],"prefix":"10.2169","volume":"96","author":[{"given":"Michinori","family":"Ogura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14: 1282-1290, 1996.","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ezdinli EZ, et al: Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3: 769-775, 1985.","DOI":"10.1200\/JCO.1985.3.6.769"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Dana BW, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11: 644-651, 1993.","DOI":"10.1200\/JCO.1993.11.4.644"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) PW Johnson, et al: Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13: 140-147, 1995.","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Advani R, et al: Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22: 1454-1459, 2004.","DOI":"10.1200\/JCO.2004.10.086"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Maloney DG, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274, 1997.","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Maloney DG, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997.","DOI":"10.1182\/blood.V90.6.2188.2188_2188_2195"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) McLaughlin P, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Igarashi T, et al: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 13: 928-943, 2002.","DOI":"10.1093\/annonc\/mdf155"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Colombat P, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97: 101-106, 2001.","DOI":"10.1182\/blood.V97.1.101"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hainsworth JD, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21: 1746-1751, 2003.","DOI":"10.1200\/JCO.2003.09.027"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ghielmini M, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103: 4416-4423, 2004.","DOI":"10.1182\/blood-2003-10-3411"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) van Oers MH, et al: Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108: 3295-3301, 2006.","DOI":"10.1182\/blood-2006-05-021113"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hochster HS, et al: Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (ASH Annual Meeting Abstracts) 106: 349, 2005.","DOI":"10.1182\/blood.V106.11.349.349"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Czuczman MS, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268-276, 1999.","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ogura M, et al: Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci 97: 305-312, 2006.","DOI":"10.1111\/j.1349-7006.2006.00173.x"},{"key":"17","unstructured":"17) Czuczman MS, et al: Progerssion-Free Survival (PFS) After Six Years (Median) Follow Up of the First Clinical Trial of Rituximab\/CHOP Chemoimmunotherapy. Blood (Suppl), 2001."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Czuczman MS, et al: Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. J Clin Oncol 22: 4711-4716, 2004.","DOI":"10.1200\/JCO.2004.04.020"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Czuczman MS, et al: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23: 694-704, 2005.","DOI":"10.1200\/JCO.2005.02.172"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Marcus R, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417-1423, 2005.","DOI":"10.1182\/blood-2004-08-3175"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hiddemann, W, et al: Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 106: 3725-3732, 2005.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Forstpointner R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104: 3064-3071, 2004.","DOI":"10.1182\/blood-2004-04-1323"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Horning SJ, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97: 404-409, 2001.","DOI":"10.1182\/blood.V97.2.404"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Lenz G, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104: 2667-2674, 2004.","DOI":"10.1182\/blood-2004-03-0982"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ogura M, et al: Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol 80: 267-277, 2004.","DOI":"10.1532\/IJH97.04077"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Gribben JG, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525-1533, 1991.","DOI":"10.1056\/NEJM199111283252201"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Freedman AS, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94: 3325-3333, 1999.","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Voso MT, et al: In vivo depletion of B cells using a combination of high-dose cytosine arabinoside\/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109: 729-735, 2000.","DOI":"10.1046\/j.1365-2141.2000.02084.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Magni M, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96: 864-869, 2000.","DOI":"10.1182\/blood.V96.3.864"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ogura M, et al: Phase I\/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphomas. Int J Hematol 77: 503-511, 2003.","DOI":"10.1007\/BF02986620"},{"key":"31","unstructured":"31) Ogura M, et al: Phase I\/II Study of a New Salvage Chemotherapy with Rituximab (CHASER Therapy) for Relapsed Advanced Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). Blood abstr 4713, 2002."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Khouri IF, et al: Transplant-lite: induction of graft-versus-malignancy using fludarabine- based non-ablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16: 2817-2824, 1998.","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Slavin S, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-763, 1998.","DOI":"10.1182\/blood.V91.3.756.756_756_763"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Sykes M, et al: Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353: 1755-1759, 1999.","DOI":"10.1016\/S0140-6736(98)11135-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Khouri IF, et al: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98: 3595-3599, 2001.","DOI":"10.1182\/blood.V98.13.3595"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Escalo'n MP, et al: Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation. J Clin Oncol 22: 2419-2423, 2004.","DOI":"10.1200\/JCO.2004.09.092"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Fisher RI, et al: New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. J Clin Oncol 23: 8447-8452, 2005.","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Witzig TE, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002.","DOI":"10.1200\/JCO.2002.11.076"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kaminski MS, et al: 31I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441-449, 2005.","DOI":"10.1056\/NEJMoa041511"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/96\/4\/96_787\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T16:41:30Z","timestamp":1621442490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/96\/4\/96_787\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.96.787","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}